Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic stem cell transplantation (HSCT) promotes hematopoiesis by inducing HSC pr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Hematol Oncol
Glavni autori: Green, Michael M. B., Chao, Nelson, Chhabra, Saurabh, Corbet, Kelly, Gasparetto, Cristina, Horwitz, Ari, Li, Zhiguo, Venkata, Jagadish Kummetha, Long, Gwynn, Mims, Alice, Rizzieri, David, Sarantopoulos, Stefanie, Stuart, Robert, Sung, Anthony D., Sullivan, Keith M., Costa, Luciano, Horwitz, Mitchell, Kang, Yubin
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4989381/
https://ncbi.nlm.nih.gov/pubmed/27535663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0301-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items